Development of the combination therapy of anti-PD1 antibody with PAI-1 inhibitors in advanced melanoma patients

被引：0
|
作者：
Fujimura, T. [1 ]
Ohuchi, K. [1 ]
Kambayashi, Y. [1 ]
Hidaka, T. [1 ]
Asano, Y. [1 ]
机构：
[1] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi, Japan
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2022年 / 142卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
447
引用
收藏
页码：S257 / S257
页数：1
相关论文
共 50 条
  • [1] VEDOLIZUMAB PLUS ANTI-PD1 ANTIBODY IN ADVANCED MELANOMA PATIENTS WITH INFLAMMATORY ENTEROCOLITIS
    Javed, Asad
    Freesmeier, Michele
    Zakharia, Yousef
    Milhem, Mohammed
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1313 - A1313
  • [2] Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
    Brown, Lauren J.
    Weppler, Alison
    Bhave, Prachi
    Allayous, Clara
    Patrinely, J. Randall, Jr.
    Ott, Patrick
    Sandhu, Shahneen
    Haydon, Andrew
    Lebbe, Celeste
    Johnson, Douglas B.
    Long, Georgina V.
    Menzies, Alexander A.
    Carlino, Matteo S.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (05)
  • [3] The Effects of Brain Metastases in Melanoma Patients on anti-PD1 Antibody Therapy with Pembrolizumab
    Weichenthal, M.
    Mohr, P.
    Leiter-Stoeppke, U.
    Ugurel, S.
    Kaehler, K.
    Gutzmer, R.
    Pfoehler, C.
    Hassel, J. C.
    Nashan, D.
    Terheyden, P.
    Schell, B.
    Utikal, J. S.
    Kreuter, A.
    Haferkamp, S.
    Kaune, K.
    Berking, C.
    Debus, D.
    Ulrich, J.
    Dabrowski, E.
    Eigentler, T.
    Welzel, J.
    Herbst, R.
    Loquai, C.
    Meier, F.
    Schadendorf, D.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 5 - 6
  • [4] Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma
    Albrecht, L. J.
    Dimitriou, F.
    Grover, P.
    Hassel, J. C.
    Erdmann, M.
    Forschner, A.
    Johnson, D.
    Livingstone, E.
    Roesch, A.
    Ugurel, S.
    Schulz, C.
    Berking, C.
    Menzies, A. M.
    Long, G. V.
    Dummer, R.
    Schadendorf, D.
    Zimmer, L.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 44 - 44
  • [5] Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
    Ohuchi, Kentaro
    Kambayashi, Yumi
    Hidaka, Takanori
    Fujimura, Taku
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop
    Lorigan, P.
    Eggermont, A. M. M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (07) : 1038 - 1040
  • [7] Kinase inhibition and anti-PD1 combination therapy
    Collingridge, David
    [J]. LANCET ONCOLOGY, 2020, 21 (07): : 886 - 886
  • [8] Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy
    Fujimura, Taku
    Kambayashi, Yumi
    Ohuchi, Kentaro
    Amagai, Ryo
    Sato, Yota
    Tanita, Kayo
    Hashimoto, Akira
    Aiba, Setsuya
    [J]. CASE REPORTS IN ONCOLOGY, 2020, 13 (01): : 271 - 275
  • [9] Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.
    Zimmer, Lisa
    Dimitriou, Florentia
    Grover, Piyush
    Hassel, Jessica Cecile
    Erdmann, Michael
    Forschner, Andrea
    Johnson, Douglas Buckner
    Livingstone, Elisabeth
    Roesch, Alexander
    Ugurel, Selma
    Schulz, Carsten
    Berking, Carola
    Menzies, Alexander M.
    Long, Georgina V.
    Dummer, Reinhard
    Schadendorf, Dirk
    Albrecht, Lea Jessica
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] ANTI-PD1 THERAPY IN PATIENTS WITH METASTATIC MELANOMA: A SINGLE CENTRE EXPERIENCE
    Nguyen, B.
    Robinson, E.
    Arora, A.
    Sayed, A.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 65 - 65
12345